Replimune Group (REPL) News Today $5.38 -0.15 (-2.71%) Closing price 04:00 PM EasternExtended Trading$5.41 +0.03 (+0.56%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky2 hours ago | globenewswire.comREPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit3 hours ago | globenewswire.comInvestors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPLAugust 28 at 11:27 AM | theglobeandmail.comReplimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPLAugust 28 at 8:45 AM | prnewswire.comPrice T Rowe Associates Inc. MD Sells 109,051 Shares of Replimune Group, Inc. $REPLAugust 28 at 5:06 AM | marketbeat.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law FirmAugust 27 at 5:58 PM | prnewswire.comSeptember 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPLAugust 27 at 4:29 PM | globenewswire.comKirby McInerney LLP Reminds Replimune Group, Inc. Investors of Class Action Filing and Encourages Investors to Contact the FirmAugust 27 at 4:19 PM | globenewswire.comReplimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens BermanAugust 27 at 1:20 PM | globenewswire.comNuveen LLC Acquires Shares of 671,411 Replimune Group, Inc. $REPLAugust 27 at 3:38 AM | marketbeat.comReplimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPLAugust 26 at 8:46 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLAugust 25 at 10:00 PM | prnewswire.comKessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. Investors of Important Deadline in Securities Fraud Class Action LawsuitAugust 25 at 5:49 PM | theglobeandmail.comReplimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens BermanAugust 25 at 4:17 PM | globenewswire.comROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPLAugust 25 at 12:56 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLAugust 25 at 10:46 AM | globenewswire.comClass Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors - Contact The Gross Law FirmAugust 25 at 8:45 AM | prnewswire.comSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)August 25 at 8:34 AM | globenewswire.comROSEN, LEADING TRIAL COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - REPLAugust 24, 2025 | markets.businessinsider.comClass Action Announcement for Replimune Group, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Replimune Group, Inc. - Contact Kessler Topaz Meltzer ...August 23, 2025 | theglobeandmail.comROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPLAugust 22, 2025 | globenewswire.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law FirmAugust 22, 2025 | prnewswire.comLost Money on Replimune Group, Inc.(REPL)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAugust 22, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLAugust 22, 2025 | prnewswire.comShareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPLAugust 22, 2025 | prnewswire.comInsider Selling: Replimune Group (NASDAQ:REPL) CFO Sells 9,154 Shares of StockAugust 21, 2025 | marketbeat.comREPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAugust 21, 2025 | globenewswire.comClass Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact The Gross Law FirmAugust 21, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLAugust 21, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneAugust 21, 2025 | prnewswire.comReplimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPAugust 20, 2025 | theglobeandmail.comInvestors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025August 20, 2025 | theglobeandmail.comInvestors Who Lost Money on Replimune Group, Inc. (REPL) Should Contact Levi & Korsinsky About Pending Class Action - REPLAugust 20, 2025 | theglobeandmail.comREPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLPAugust 20, 2025 | globenewswire.comReplimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens BermanAugust 20, 2025 | globenewswire.comShareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPLAugust 19, 2025 | globenewswire.comClass Action Filed Against Replimune Group, Inc. ...August 19, 2025 | gurufocus.comClass Action Filed Against Replimune Group, Inc. (REPL) - September 22, 2025 Deadline to Join - Contact Levi & KorsinskyAugust 19, 2025 | prnewswire.comReplimune Group, Inc. (NASDAQ:REPL) Receives $7.67 Average Target Price from AnalystsAugust 19, 2025 | americanbankingnews.comReplimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. ...August 18, 2025 | gurufocus.comReplimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPLAugust 18, 2025 | globenewswire.comReplimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens BermanAugust 18, 2025 | globenewswire.comContact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL)August 18, 2025 | prnewswire.comShort Interest in Replimune Group, Inc. (NASDAQ:REPL) Increases By 165.7%August 18, 2025 | marketbeat.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. ...August 18, 2025 | gurufocus.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 18, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLAugust 17, 2025 | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. ...August 16, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLAugust 16, 2025 | prnewswire.comReplimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens BermanAugust 15, 2025 | globenewswire.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.250.99▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼277▲REPL Articles Average Week Get the Latest News and Ratings for REPL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Replimune Group and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Apogee Therapeutics News Beam Therapeutics News Immunocore News Cidara Therapeutics News Aurinia Pharmaceuticals News Biohaven News WAVE Life Sciences News Travere Therapeutics News Tilray Brands News Edgewise Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access